Page last updated: 2024-11-08

mibolerone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mibolerone: prevents estrus in animals & prevents experimental lymphoid leukosis; minor descriptor (80-83); on-line & Index Medicus search NANDROLONE/AA (80-83); RN given refers to (7alpha,17beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mibolerone : An androgen that is nalandrone carrying two methyl substituents at positions 7alpha and 17. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID251636
CHEMBL ID425863
CHEBI ID34849
SCHEMBL ID565277
MeSH IDM0262540

Synonyms (77)

Synonym
[3h]mib
[3h]mibolerone
(1s,2r,9r,10r,11s,14s,15s)-14-hydroxy-9,14,15-trimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
bdbm26258
gtpl2859
(7alpha,17beta)-17-hydroxy-7,17-dimethylestr-4-en-3-one
cheque drops
17beta-hydroxy-7alpha,17-dimethylestr-4-en-3-one
estr-4-en-3-one, 17beta-hydroxy-7alpha,17-dimethyl-
cheque (veterinary)
einecs 223-046-5
estr-4-en-3-one, 17-beta-hydroxy-7-alpha,17-dimethyl-
miboleronum [inn-latin]
estr-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7alpha,17beta)-
7alpha,17-dimethyl-19-nortestosterone
estr-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7-alpha,17-beta)-
mibolerona [inn-spanish]
19-nortestosterone, 7alpha,17-dimethyl-
nsc 72260
7alpha,17alpha-dimethyl-19-nortestosterone
brn 5565683
7-alpha-17-alpha-dimethyl-19-nortestosterone
17-beta-hydroxy-7,17-dimethylestr-4-en-3-one
estr-4-en-3-one,17-dimethyl-, (7.alpha.,17.beta.)-
nsc-72260
cdb 904
3704-09-4
u-10,997
mibolerone
7-.alpha.-17-.alpha.-dimethyl-19-nortestosterone
nsc72260
miboleron
u 10997
17-beta-hydroxy-7-alpha,17-dimethylestr-4-en-3-one
17,17-dimethyl-19-nortestosterone
mobilerone
u-10997
mibolerone (usp/inn)
D05025
(7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13,17-trimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
dihydrolone
mibolerone ciii
u-10-997
chebi:34849 ,
CHEMBL425863
mibolerone [usan:usp:inn:ban]
9ogy4bor8d ,
unii-9ogy4bor8d
mibolerona
cheque
miboleronum
7alpha,17alpha-dimethyl-17beta-hydroxyestr-4-en-3-one
7alpha-17alpha-dimethyl-19-nortestosterone
mibolerone [green book]
mibolerone [usp monograph]
mibolerone [usan]
mibolerone [mart.]
mibolerone [inn]
mibolerone [mi]
mibolerone ciii [usp-rs]
gtpl3456
SCHEMBL565277
dtxcid2016489
tox21_113738
cas-3704-09-4
NCGC00253603-01
dtxsid4036489 ,
DB11429
Q6827784
estr-4-en-3-one, 17-hydroxy-7,17-dimethyl-, (7.beta.,8.epsilon.,9.beta.,10.alpha.,13.alpha.,14.beta.,17.alpha.)-
mibolerona (inn-spanish)
miboleronum (inn-latin)
mibolerone (usp monograph)
cheque medicated dog food
mibolerone ciii (usp-rs)
mibolerone (usan:usp:inn:ban)
mibolerone (mart.)

Research Excerpts

Overview

Mibolerone (1) was found to be a moderate inhibitor of β-glucuronidase enzyme (IC50 = 42.98 ± 1.24 μM) While its metabolites 2-4, and 8 were found tobe inactive.

ExcerptReferenceRelevance
"Mibolerone (1) was found to be a moderate inhibitor of β-glucuronidase enzyme (IC50 = 42.98 ± 1.24 μM) during random biological screening, while its metabolites 2-4, and 8 were found to be inactive."( Biotransformation of a potent anabolic steroid, mibolerone, with Cunninghamella blakesleeana, C. echinulata, and Macrophomina phaseolina, and biological activity evaluation of its metabolites.
Ahmad, MS; Choudhary, MI; Fatima, N; Naveed Shaikh, N; Rahman, AU; Siddiqui, M; Wahab, AT; Yousuf, S, 2017
)
1.43

Treatment

Mibolerone (100 nM) was unable to alter the action of TPA on androgen synthesis when doses of 1 and 10 nM TPA were employed. Treatment with miboleranceone reduced this cAMP-stimulated androgenogenesis by 51%.

ExcerptReferenceRelevance
"Mibolerone-treated birds lacked natural agglutinins to rabbit red blood cells."( Chickens bursectomized with mibolerone have Ig-positive cells which lack bursal cell specific antigens.
Bhanushali, JK; Ragland, WL, 1985
)
1.28
"Mibolerone-treated chicks were subsequently challenged with sheep red blood cells (SRBC) and Brucella abortus at 1, 7, 14, or 21 days of age."( Delayed development of humoral immunity in chickens following in ovo treatment with mibolerone.
Bhanushali, JK; Murthy, KK; Ragland, WL, 1985
)
1.22
"When mibolerone-treated birds were challenged with sheep red blood cells and killed Brucella abortus at 4 and 5 weeks of age, birds treated with 10 or 100 micrograms of mibolerone had suppressed humoral responses to sheep erythrocytes and B."( The effects of in ovo mibolerone treatment on the bursa of Fabricius and the humoral system of chickens: a dose-response study.
Bhanushali, JK; Murthy, KK; Ragland, WL, 1985
)
1.04
"Treatment with mibolerone (100 nM) was unable to alter the action of TPA on androgen synthesis when doses of 1 and 10 nM TPA were employed."( Mechanisms of action for an androgen-mediated autoregulatory process in rat thecal-interstitial cells.
Chorich, LP; Mahesh, VB; Simone, DA, 1993
)
0.63
"Treatment with mibolerone (100 nM), however, reduced this cAMP-stimulated androgen synthesis by 51%."( An autoregulatory process for androgen production in rat thecal-interstitial cells.
Mahesh, VB; Simone, DA, 1993
)
0.63

Dosage Studied

ExcerptRelevanceReference
"A controlled, blind-labeled, dose-response field trial was conducted to evaluate the efficacy of mibolerone as a treatment for pseudopregnancy in the bitch."( Efficacy and dosage titration study of mibolerone for treatment of pseudopregnancy in the bitch.
Brown, JM, 1984
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
anabolic agentA compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power.
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
17beta-hydroxy steroidA 17-hydroxy steroid in which the hydroxy group at position 17 has a beta-configuration.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.73370.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency21.27180.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency0.21230.000221.22318,912.5098AID1259247; AID1259381
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency1.94560.000657.913322,387.1992AID1259377; AID1259378; AID1259394
progesterone receptorHomo sapiens (human)Potency0.00170.000417.946075.1148AID1346784; AID1347036
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency18.95860.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.15550.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency15.76390.000229.305416,493.5996AID1259248; AID1259383
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency31.66790.000627.21521,122.0200AID743202; AID743219
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency35.48130.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00130.00101.979414.1600AID1435108; AID255211
Androgen receptorRattus norvegicus (Norway rat)Ki0.00080.00031.21858.9270AID239949; AID39293
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID162462Relative binding affinity to the progesterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID74389Relative binding affinity against glucocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID69853Relative binding affinity against Estrogen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID238931Inhibition of rat prostate cytosolic androgen receptor2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and structure-activity investigation of iodinated arylhydantoins and arylthiohydantoins for development as androgen receptor radioligands.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID162617Relative binding affinity against progestin receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID39293Binding affinity against rat prostate cytosolic Androgen receptor using [3H]mibolerone as radioligand2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Synthesis and structure-activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands.
AID239949Inhibition of [3H]mibolerone binding to cytosolic androgen receptor of rat ventral prostate2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain.
AID39296Inhibitory constant against rat prostate cytosol androgen receptor using [3H]mibolerone2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand.
AID1435108Displacement of [3H]-MIB from rat prostate cytosolic androgen receptor by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 03-01, Volume: 25, Issue:5
Synthesis of new derivatives of 21-imidazolyl-16-dehydropregnenolone as inhibitors of 5α-reductase 2 and with cytotoxic activity in cancer cells.
AID39454Relative binding affinity against androgen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID39451Binding affinity against cytosolic androgen receptor from ventral prostate of rats using [3H]MIB competitive binding assay (relative to dihydro testosterone)2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor.
AID212922Relative binding affinity to the testosterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID126441Relative binding affinity for the mineralocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID1346911Rat Androgen receptor (3C. 3-Ketosteroid receptors)2003Chemical research in toxicology, Oct, Volume: 16, Issue:10
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
AID1346888Human Androgen receptor (3C. 3-Ketosteroid receptors)2000The Journal of clinical endocrinology and metabolism, Jun, Volume: 85, Issue:6
Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (163)

TimeframeStudies, This Drug (%)All Drugs %
pre-199037 (22.70)18.7374
1990's71 (43.56)18.2507
2000's35 (21.47)29.6817
2010's14 (8.59)24.3611
2020's6 (3.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.13 (24.57)
Research Supply Index5.14 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index72.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.60%)5.53%
Reviews5 (2.98%)6.00%
Case Studies6 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other156 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]